APA (7th ed.) Citation

CS, D., VL, K., V, M., G, M., & GI, S. (2021). Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Investigational new drugs, 39(6), 1604. https://doi.org/10.1007/s10637-021-01145-y

Chicago Style (17th ed.) Citation

CS, Denlinger, Keedy VL, Moyo V, MacBeath G, and Shapiro GI. "Phase 1 Dose Escalation Study of Seribantumab (MM-121), an Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors." Investigational New Drugs 39, no. 6 (2021): 1604. https://doi.org/10.1007/s10637-021-01145-y.

MLA (9th ed.) Citation

CS, Denlinger, et al. "Phase 1 Dose Escalation Study of Seribantumab (MM-121), an Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors." Investigational New Drugs, vol. 39, no. 6, 2021, p. 1604, https://doi.org/10.1007/s10637-021-01145-y.